The recent clinical success of antibodies targeting immune checkpoint molecules, such as programmed death receptor-1 (PD-1), its ligand PD-L1, and cytotoxic T cell-associated antigen 4 (CTL-A4), have led to a new and strong interest in the field of cancer immunotherapy [1,2]. This evidence concerns the gene CD274 and cancer.